|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||
| Current assets: | ||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||
| Restricted cash | ||||||||||||||||
| Short-term investments available for sale | ||||||||||||||||
| Accounts receivable, net | ||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||
| Deferred offering costs | ||||||||||||||||
| Total current assets | ||||||||||||||||
| Property and equipment, net | ||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||
| Intangible assets, net | ||||||||||||||||
| Goodwill | ||||||||||||||||
| Other assets | ||||||||||||||||
| Total assets | ||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||||||||||||||||
| Accounts payable | ||||||||||||||||
| Accrued expenses and other current liabilities | ||||||||||||||||
| Deferred revenue | ||||||||||||||||
| Deferred purchase consideration – current portion | ||||||||||||||||
| Operating lease liabilities – current portion | ||||||||||||||||
| Notes payable, net of debt discount and warrant allocation of $376 and $1,267 as of June 30, 2025 and December 31, 2024, respectively | ||||||||||||||||
| Forward share purchase agreements derivative liability | ||||||||||||||||
| Total current liabilities | ||||||||||||||||
| Operating lease liabilities – non-current portion | ||||||||||||||||
| Notes payable – non-current portion, net of debt discount and warrant allocation of $4,563 as of December 31, 2023 | ||||||||||||||||
| Deferred purchase consideration – non-current portion | ||||||||||||||||
| Other non-current liabilities | ||||||||||||||||
| Total liabilities | ||||||||||||||||
| Redeemable Preferred Stock - Mezzanine Equity beginning balance | ||||||||||||||||
| Stockholders’ deficit: | ||||||||||||||||
| Common stock, $0.0001 par value; 110,000 shares authorized as of both June 30, 2025 and December 31, 2024; 51,368 and 50,261 issued and outstanding as of June 30, 2025 and December 31, 2024, respectively | ||||||||||||||||
| Additional paid-in capital | ||||||||||||||||
| Accumulated deficit | ||||||||||||||||
| Total stockholders’ deficit | ||||||||||||||||
| Total liabilities and stockholders’ deficit | ||||||||||||||||
Loading...
